AstraZeneca
AstraZeneca, Daiichi say Enhertu delivers ‘highly statistically significant’ efficacy in first-line breast cancer
Enhertu, fam-trastuzumab deruxtecan-nxki, AstraZeneca, Daiichi Sankyo, HER2-positive metastatic breast cancer, first-line therapy, progression-free survival, antibody drug conjugate (ADC), pertuzumab
Rocket Pharmaceuticals Expands Leadership with J&J and AstraZeneca Alumni to Strengthen Gene Therapy Commercialization
Rocket Pharmaceuticals, gene therapy, commercial leadership, Sarbani Chaudhuri, Johnson & Johnson, AstraZeneca, commercial launch, gene therapy market, rare diseases, biotechnology, Kresladi, RP-L102.
AstraZeneca details $2.5B investment in China’s political center, funding R&D center, biotech pacts
Investments, AstraZeneca, Beijing, China, China ‘s, Collaboration
AstraZeneca deepens cell therapy expansion with $1B EsoBiotec buyout
AstraZeneca, EsoBiotec, cell therapy, acquisition, ENaBL platform, in vivo cell engineering, oncology, autoimmune diseases
AstraZeneca Inks $1.35B Deal with Alteogen for Subcutaneous Cancer Drugs Amid Industry Patent Disputes
AstraZeneca, Alteogen, subcutaneous cancer drugs, licensing agreement, patent dispute, Merck, Halozyme, hyaluronidase enzyme
AstraZeneca to acquire FibroGen’s China unit for $160M
China, AstraZeneca, FibroGen, FibroGen ‘s, roxadustat
AstraZeneca Acquires FibroGen’s China Unit for $160 Million, Gaining Full Control of Anemia Drug Roxadustat
AstraZeneca, FibroGen, China, acquisition, roxadustat, anemia, chronic kidney disease, pharmaceutical industry
AstraZeneca Shares Rise as China Investigation Impact Appears Limited
AstraZeneca, China investigation, share price, financial performance, import taxes, investor confidence
AstraZeneca Discontinues Vemircopan, Takes $753M Charge on Former Alexion Asset
AstraZeneca, Alexion, vemircopan, complement inhibitor, drug discontinuation, impairment charge, rare diseases, pharmaceutical industry